Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-022-00419-6
Updates & Corrections
-
Correction 23 February 2022: An earlier version of this article misspelled Rajesh Gandhi’s name.
References
Iketani, S. et al. Preprint at bioRxiv https://doi.org/10.1101/2022.02.07.479306 (2022).
Zhou, H., Tada, T., Dcosta, B. M. & Landau, N. R. Preprint at bioRxiv https://doi.org/10.1101/2022.02.15.480166 (2022).
Westendorf, K. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.04.30.442182 (2022).
Aggarwal, A. et al. Preprint at medRxiv https://doi.org/10.1101/2021.12.14.21267772 (2021).
Yamasoba, D. et al. Preprint at bioRxiv https://doi.org/10.1101/2022.02.14.480335 (2022).
Cathcart, A. L., et al. Preprint at medRxiv https://www.biorxiv.org/content/10.1101/2021.03.09.434607v11 (2022).
Omicron overpowers key COVID antibody treatments in early tests
COVID antibody treatments show promise for preventing severe disease
Coronapod: Why COVID antibody treatments may not be the answer
The race to make COVID antibody therapies cheaper and more potent
